Oragenics, Inc. Selects Qualia Clinical Services to Conduct SMaRT(TM) Phase 1 Trial

ALACHUA, FL--(Marketwire - December 05, 2007) - Oragenics, Inc. (AMEX: ONI), a biotechnology development company focused on infectious diseases and cancer, announced today that Qualia Clinical Services, located in Omaha, Nebraska, has been selected to provide clinical site services for the Company's recently approved Phase 1b safety trial. The trial will be conducted in compliance with the approved FDA protocol and is designed to evaluate the safety and tolerability of the Company's SMaRT Replacement Therapy™ in healthy, adult male subjects over a six-week period, with a long-term follow-up evaluation at six months.

Back to news